Ocular Therapeutix, Inc. (OCUL)
After hours:
| Previous close | 5.84 |
| Open | 5.90 |
| Bid | 5.64 x 1800 |
| Ask | 5.68 x 1800 |
| Day's range | 5.35 - 5.95 |
| 52-week range | 2.00 - 11.31 |
| Volume | |
| Avg. volume | 2,752,480 |
| Market cap | 904.553M |
| Beta (5Y monthly) | 1.46 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.12 |
| Earnings date | 05 Aug 2024 - 09 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 14.50 |
GuruFocus.comOcular Therapeutix Inc Reports First Quarter 2024 Earnings
Financial Performance and Strategic Developments Highlighted
GlobeNewswireOcular Therapeutix™ Reports First Quarter 2024 Results
Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects Randomized in April 2024 Cash Expected to Support Operations Into 2028, Based on $482.9M March 31, 2024, Cash Balance June 13, 2024, Investor Day to Outline Updated Corporate Strategy BEDFORD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a bi
- GlobeNewswire
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it has agreed to grant inducement awards to (i) its newly appointed Vice President, Head of Programmin
